IRVINE, CA -- (Marketwire) -- 05/08/12 -- BIOLASE Technology, Inc. (NASDAQ: BLTI), the World's leading dental laser manufacturer and distributor, today announced that management is scheduled to make investor presentations at three upcoming investment conferences.
The first conference will be Security Research Associates' 8th Annual Spring Growth Stock Conference on Tuesday, May 15, during which CFO and COO Frederick Furry is scheduled to present at 2:30 pm Pacific Time. The conference is being held at the Le Meridien Hotel in San Francisco. A live audio webcast of the presentation at this conference will be available in the Investors section of the BIOLASE website at www.biolase.com.
The second conference will be the 13th Annual B. Riley & Co. Investor Conference on Wednesday, May 23, during which CFO and COO Frederick Furry is scheduled to present at 2:00 pm Pacific Time. The conference is being held at the Loews Santa Monica Beach Hotel in Santa Monica, CA.
The third conference will be SunTrust Robinson Humphrey's Annual Veterinary and Dental Conference on Wednesday, May 30, during which Chairman and CEO Federico Pignatelli is scheduled to host one-on-one and small group meetings throughout the day. The conference is being held at the Le Meridien Hotel in New York City.
About BIOLASE Technology, Inc.
BIOLASE Technology, Inc., the World's leading Dental Laser Company, is a medical technology company that develops, manufactures and markets dental lasers and also distributes and markets dental imaging equipment, products that are focused on technologies that advance the practice of dentistry and medicine. The Company's laser products incorporate 285 patented and patent pending technologies designed to provide clinically superior performance with less pain and faster recovery times. Its imaging products provide cutting-edge technology at competitive prices to deliver the best results for dentists and patients. BIOLASE's principal products are dental laser systems that perform a broad range of dental procedures, including cosmetic and complex surgical applications, and a full line of dental imaging equipment. BIOLASE has sold more than 19,000 lasers among 16,000 customers. Other products under development address ophthalmology and other medical and consumer markets.
This press release may contain forward-looking statements within the meaning of safe harbor provided by the Securities Reform Act of 1995 that are based on the current expectations and estimates by BIOLASE management. These forward-looking statements can be identified through the use of words such as "anticipates," "expects," "intends," "plans," "believes," "seeks," "estimates," "may," "will," and variations of these words or similar expressions. Forward-looking statements are based on management's current, preliminary expectations and are subject to risks, uncertainties and other factors which may cause the Company's actual results to differ materially from the statements contained herein, and are described in the Company's reports it files with the Securities and Exchange Commission, including its annual and quarterly reports. No undue reliance should be placed on forward-looking statements. Such information is subject to change, and BIOLASE undertakes no obligation to update such statements.
For further information, please contact:
Allen & Caron